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Summary The effects of altering the timing of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration on
neutropenia induced by cyclophosphamide (CPA) were studied experimentally in a mouse model. Experimental mice were divided into three
groups: (a) treatment with rhG-CSF after CPA administration (post-treatment group); (b) treatment with rhG-CSF both before and after CPA
administration (pre- and post-treatment group); and (c) treatment with saline after CPA administration (control group). The results were as
follows. Mice receiving rhG-CSF on the 2 days preceding CPA treatment, in which progenitor cell counts outside the S-phase when CPA was
administered were the lowest of all the groups, showed accelerated neutrophil recovery but decreased neutrophil nadirs compared with the
control group despite rhG-CSF treatment. The pre- and post-treatment group, consisting of mice who received rhG-CSF treatment on days -4
and -3 before CPA treatment, and in which progenitor cell counts when CPA was administered were increased to greater levels than in the
other groups, showed remarkably accelerated neutrophil recovery and the greatest increase in the neutrophil nadirs of all the groups. These
results suggested that the kinetics of progenitor cell populations when chemotherapeutic agents were administered seemed to play an
important role in neutropenia after chemotherapy, and that not only peripheral neutrophil cell and total progenitor cell counts but also
progenitor cell kinetics should be taken into consideration when administering rhG-CSF treatment against the effects of chemotherapy.
Keywords: recombinant human granulocyte colony stimulating-factor; the timing of rhG-CSF administration; cyclophosphamide;
chemotherapy
Neutropenia is a major factor contributing to infection and
mortality in patients undergoing chemotherapy for cancer. It can
limit drug dosages and the frequency oftreatment and is one ofthe
dose-limiting factors in anti-cancer chemotherapy. Recombinant
human granulocyte colony-stimulating factor (rhG-CSF) promotes
proliferation and differentiation of granulocyte colony-forming
progenitor cells (progenitor cells) and induces an increase in
neutrophils in peripheral blood (Okabe et al, 1990; Takaue et al,
1990; Tanaka et al, 1991). Recently, clinical studies on rhG-CSF
administration after chemotherapy have reported that rhG-CSF
induces accelerated recovery from neutropenia, as evidenced by
leucocyte or neutrophil counts (Gabrilove et al, 1988; Crawford et
al, 1991; Sarosy et al, 1992). However, changes in granulopoietic
activity with alterations in the timing of rhG-CSF administration
on neutropenia induced by chemotherapy still remains unclear.
Furthermore, expansions in granulocyte progenitor cell popula-
tions, which play an important role in granulopoiesis, have not
been investigated in detail. By investigating the expansion of pro-
genitor cell populations, as well as neutrophil counts, we studied
the effects of altering the timing of rhG-CSF administration on
neutropenia induced by cyclophosphamide (CPA) in normal mice.
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MATERIALS AND METHODS
Mice and rhG-CSF administration
Female C57BL mice, aged 8-10 weeks, received a single
220 mgkg-' i.p. dose of CPA (Shionogi Seiyaku, Tokyo, Japan).
Experimental mice also received 5 mg per body per day rhG-CSF
(Kyowa Hakko Kogyo, Tokyo, Japan) s.c. in a 0.2-ml volume on the
following schedule: treatment with rhG-CSF after CPA administra-
tion (post-treatment group), treatment with rhG-CSFboth before and
after CPA administration (pre- and post-treatment group). After
investigating the effects of2 days ofrhG-CSF pretreatment on prog-
enitor cells, the pre- and post-treatment group was subdivided into
another two groups according to the number of progenitor cells
outside the DNA synthesis when CPA was administered. In group A,
CPA was administered when progenitor cell counts, excluding cells
in the S-phase, were reduced by rhG-CSF pretreatment that was
given on days -1 and -2. In group B, CPA was administered when
progenitor cell counts, excluding cells in the S-phase, peaked after
rhG-CSF pretreatment that was given on days -3 and -4. Control
mice received 0.2 ml of 0.9% sodium chloride on each of
4 days after CPA administration (Table 1).
Peripheral blood neutrophils
Twenty-four hours afterinjection, blood samples were obtained by
cardiac puncture and total leucocyte counts were determined.
Differential leucocyte counts were analysed on Wright-Giemsa-
stained blood smears and final neutrophil counts were determined.
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Colony-forming unit assay
Twenty-four hours after injection, bone marrow nucleated cells
were obtained aseptically from the femur. To evaluate granulocyte
colony formation, bone marrow cells were suspended at 1 x 105
cells perml in 0.3% agarcontaining a-MEM, 20% fetal calfserum
(FCS), and 40 ng per ml of rhG-CSF. Cells were then transferred
to 35-mm culture dishes, and incubated at 37°C in 5% carbon-
dioxide for at least 7 days. Colonies containing more than 40 cells
were enumerated as progenitor cells and were expressed as the
number ofcolonies per femur.
[3H]thymidine suicide assay
Bone marrow nucleated cells were suspended at a density of 2 x
106 cells per ml of a-MEM. Cell suspensions (1.0 ml) were incu-
bated with or without [3H]thymidine (spec. act. 925 GBq mmol-1,
Amersham, Little Chalfont, Buckinghamshire, UK) for 20 min.
Subsequently, cells were washed with a-MEM containing
100 gg ml-l unlabelled thymidine, and then assayed for colony-
forming ability. Cells exposed to high specific activity [3H]thymi-
dine during DNA synthesis undergo a loss of colony-forming
ability because of the lethal effect of the decay of incorporated
tritium. The percentage of progenitor cells during the DNA
synthesis (suicide rate) was determined by a comparison ofcolony
numbers after in vitro treatment with high specific activity [3H]-
thymidine, and treatment without [3H]thymidine. Subsequently,
the number ofprogenitor cells in the S-phase (S-phase progenitor
cells) and the number not in the S-phase (progenitor cells outside
the S-phase) was enumerated.
Statistical analysis
The average number ofneutrophils, total progenitor cells, S-phase
progenitor cells and progenitor cells outside the S-phase were
analysed by the Mann-Whitney test (Bruning et al, 1987).
RESULTS
Effects of 2 days of rhG-CSF administration on
neutrophil counts and expansion of progenitor cell
populations (Figure 1)
To evaluate the effects of short-term rhG-CSF administration as a
pretreatment, we injected rhG-CSF for 2 consecutive days and
evaluated peripheral neutrophil counts as well as the expansion of
granulocyte progenitor cell populations. Immediately after rhG-
CSF administration, neutrophil counts increased gradually and
reached a peak on day 2, after which neutrophil counts retumed to
control values.
Progenitor cell counts peaked on day 1 after rhG-CSF adminis-
tration. Subsequently, in contrast to neutrophil counts, progenitor
cell counts retumed to control values on day 2 and then showed a
slight increase on day 4.
Suicide rates gradually increased in accordance with rhG-CSF
administration and peaked (85%) on day 2. Remarkably, the
suicide rate decreased to nadir (11%) on day 4 and the S-phase
progenitor cells similarly decreased to nadir. In contrast, the
number ofprogenitor cells not in the S-phase decreased on day 2,
and then increased markedly on day 4.
Effects of post-treatment with rhG-CSF on neutrophil
counts and progenitor cell counts after CPA
administration (Figure 2)
In control mice, neutrophil counts after CPA administration gradu-
ally decreased to nadir from day 3 to day 4. This decrease was
followed by a rapid recovery on day 5. Conversely, progenitor cell
counts dropped rapidly to nadir on day 1, and recovered by day 3.
In the post-treatment group, although the neutrophil count nadirs
were similar to that in the control group, neutrophil counts
increased rapidly on day 4 and there was a shortening ofthe period
of neutropenia. However, in the post-treatment group, progenitor
cell counts did not rise above initial levels until day4, andrecovery
was not promoted despite rhG-CSF administration.
Effects of post-treatment with rhG-CSF on the suicide
rate and S-phase progenitor cells after CPA
administration (Figure 3)
The suicide rate in both groups, which was approximately 60%
before CPA administration, dropped markedly to 0% on day 1 and
S-phase progenitor cells disappeared completely afterCPA admin-
istration. Subsequently, suicide rates rose to about 80% on day 2,
and there was a rapid recovery above the starting level, which was
sustained until day 4.
S-phase progenitor cells in both control group and post-treat-
ment with rhG-CSF disappeared on the next day after CPA admin-
istration and progenitor cells outside the S-phase only existed on
the day after CPA administration. In the control group, S-phase
progenitor cell counts increased considerably from day 3 to day 4,
whereas in post-treatment with rhG-CSF group they had only a
tendency to increase slightly, and S-phase progenitor cell counts
did not increase compared with the control group, despite rhG-
CSF administration.
Effect of pre- and post-treatment with rhG-CSF on the
suicide rate and S-phase progenitor cell counts after
CPA administration (Figure 4)
In both group A and group B, the suicide rate dropped to 0% on
day 1 after CPA administration, then showed rapid recovery on
day 2. All of the S-phase progenitor cells disappeared completely
on day 1. In group A, despite rhG-CSF administration, S-phase
progenitor cell counts decreased from day 2 to day 4 compared
with the control group. However, in group B, recovery of S-phase
progenitor cells was markedly promoted until populations peaked
at day 4.
Effects of pre- and post-treatment with rhG-CSF on
neutrophil counts and progenitor cell counts.
In group A (Figure 6), neutrophil counts decreased from day 1 to
day 3 compared with the control group, and the neutrophil count
nadir decreased in all groups, although shortening ofthe period of
neutropenia was achieved on day 4. Progenitor cell counts also
decreased from day 1 to day 3 compared with the control group,
and the nadir was further reduced in all groups.
In contrast, group B showed the highest neutrophil count nadir
and the most accelerated neutrophil recovery of all groups from
day 2 to day 4 (Figure 6). Theprogenitorcell count nadirincreased
and recovery was promoted in all groups.
British Journal ofCancer (1998) 77(6), 884-889 0 Cancer Research Campaign 1998886 MMisaki etal
gs s s DISCUSSION
Control group
Post-treatment group
Pre- and post-treatment
('-. ,rn A
Group BI
0
0
.V5.
-2 -1 0
L3-2 -1Lo
-3 __ - 0
; CPA 220 mg kg-
| rhG-CSF 5 g p
^ 0.9% sodium chi
Figure 1 Different protocols of rhG-CSF administration
1 2 3 4 In this study, we investigated the effects of altering the timing
of rhG-CSF administration on CPA-induced neutropenia and
LJ-Lj 1 examined the possibility that pretreatment with rhG-CSF could
1 2 3 4 reduce or prevent CPA-induced neutropenia.
Based on known actions ofrhG-CSF in vitro and in vivo (Okabe
et al, 1990; Takaue et al, 1990; Tanaka et al, 1991), the administra-
1 2 3 4 tion of rhG-CSF would be expected to induce an increase in the
number of both neutrophils and bone marrow progenitor cells.
However, in our study, total bone marrow progenitor cells did not
1 2 3 4 show a constant increase as neutrophil counts despite rhG-CSF
Days administration. The granulopoietic effect of rhG-CSF is to stimu-
late maturation and mobilization of neutrophils from the bone
-1 marrow compartment, as well as to stimulate proliferation and
differentiation of progenitor cells (Okabe et al, 1990). Thus, this
erbody discrepancy between neutrophil and progenitor cell counts during
rhG-CSF administration was probably because rhG-CSF adminis-
loride tration induced an increase in neutrophil cell counts at the expense
ofprogenitorcells in the progenitor pool. The suicide rate increased
as rhG-CSF continued and showed that most ofthe progenitor cells
iagainst CPA were synchronized in S-phase. Although total progenitor cell
rhG-CSF
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Figure 2 Effects of rhG-CSF administrations on neutrophil counts and expansions of progenitor cells. rhG-CSF was administered from day 0 and 24 h later on
day 1. Each data point represents mean value and bars represent s.d. (n = 6)
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Figure 3 Effects of post-treatment with rhG-CSF on neutrophil counts and
progenitor cell counts. In post-treatment group, CPA was administered on day
0, and rhG-CSF was administered from days 1 to 4. Each data point
represents the mean value and bars represent s.d. (n = 6, **P < 0.01 vs
control group) respectively. Open symbols, control; closed symbols,
post-treatment group
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Figure 4 Effects of post-treatment with rhG-CSF on suicide rate and S-
phase progenitor cell counts. In post-treatment group, CPA was administered
on day 0, and rhG-CSF was administered from days 1 to 4. Each data point
represents the mean value and bars represent s.d. (n = 6, **P < 0.01 vs
control group) respectively. Open symbols, control; closed symbols, post-
treatment group
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Figure 5 Effects of pre- and post-treatment with rhG-CSF on suicide rate
and S-phase progenitor cell counts. Each data point represents the mean
and bars represent s.d. (n = 6, **P < 0.05 vs control group) respectively.
0, control; *, group A; *, group B
counts were maintained 3 days after the cessation ofrhG-CSF, the
suicide rate decreased and S-phase progenitor cells decreased
markedly to nadir. This unexpected decrease in the suicide rate and
S-phase progenitor cell counts has not been previously demon-
strated, and the reason for these effects remains unclear. Because
this decrease in the suicide rate and S-phase progenitor cells was
not accompanied by an increase in either the total progenitor cell
count or the neutrophil count, this decrease is not likely to be
attributable to either proliferation of progenitor cells or differenti-
ation to neutrophils at the expense of S-phase progenitor cells, as
promoted by rhG-CSF. Moreover, total progenitorcell counts were
maintained despite a decrease in the S-phase fraction. Thus, it is
conceivable that most ofthe progenitorcells, after synchronization
in S-phase after rhG-CSF administration, moved from S-phase
into anotherphase ofthe cell cycle simultaneously. These observa-
tions suggested that rhG-CSF administration affected not only the
total number ofprogenitor cells but also the kinetics ofprogenitor
cells even after the cessation of rhG-CSF administration.
Moreover, the effects of rhG-CSF on neutrophil and progenitor
cells in vivo were revealed to be quite different.
Regarding the effect of rhG-CSF administration before
chemotherapy, Morstyn et al (1989) reported that pretreatment
with rhG-CSF in addition to post-treatment did not increase the
nadir and there was the potential risk of inducing neutrophil
exhaustion with rhG-CSF pretreatment. In addition, Okabe et al
(1989) suggested the possibility that additional pretreatment with
rhG-CSF might render the neutropenia more serious compared
with neutropenia without rhG-CSF pretreatment. However, the
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Figure 6 Effects of pre- and post-treatment with rhG-CSF on neutrophil
counts and progenitor cell counts in group A. As a pretreatment, rhG-CSF
was administered from day -2 to -1. Each data point represents the mean
and bars s.d. (n = 6, *P < 0.05 vs control group, **P < 0.05 vs control group)
respectively. Open symbols, control; closed symbols, group A
expansion of progenitor cell populations, which was closely
related to the peripheral neutrophil counts, was not evaluated.
Moreover, the effects of specific timing of rhG-CSF pretreatment
with respect to expansion of progenitor cell populations when
chemotherapeutic agents have been administered has not been
thoroughly investigated.
In the present study, the effects of altering the timing of rhG-
CSF administration with respect to CPA treatment were examined.
The post-treatment group was relevant to the conventional clinical
situation in which rhG-CSF administration is initiated after
chemotherapy (Gabrilove et al, 1988; Crawford et al, 1991; Sarosy
et al, 1992). Although recovery of neutropenia was promoted in
this group, an increase in the nadirs ofneutrophil and total progen-
itor cell counts was not achieved compared with the control group,
despite rhG-CSF administration. Neutrophil cell counts showed
delayed changes after changes in progenitor cell populations in
both the control and post-treatment groups, and this time lag
suggests that neutrophil counts after CPA administration are
dependent upon progenitor cell counts. Thus, the neutrophil cell
count nadir after CPA administration seemed to be affected by the
progenitor cell count nadir. With regard to the kinetics of progen-
itor cells, the suicide rate decreased to 0% in all groups and all of
the progenitor cells disappeared completely after CPA administra-
tion. This suggests that only a part of progenitor cells outside the
S-phase may survive when total progenitor cell counts have
decreased to nadirafterCPA administration. In addition, the subse-
quent remarkable increase in the suicide rate suggests that residual
surviving progenitor cells that were outside the S-phase began
active cell proliferation, leading to an increase in the total number
30 -
25 -
20 -
15 -
10 -
5.
0
20
15 -
10
5-
I T
-4 -3 -2 -1 0 1 2
.Days
3I
I I
Figure 7 Effects of pre- and post-treatment with rhG-CSF on neutrophil
counts and progenitor cell counts in group B. As a pretreatment, rhG-CSF
was administered from day -4 to -3. Each data point represents the mean
and bars represent s.d. (n = 6, *P< 0.01 vs control group, **P< 0.05 vs
control group) respectively. Open symbols, control; closed symbols, group B
of progenitor cells. This may occur because the recovery of total
progenitor cells might be premature ifthe haemopoietic stem cells
supported this increase in progenitor cell populations (Ikebuchi et
al, 1988). As discussed previously, short-term rhG-CSF adminis-
tration affected the kinetics of progenitor cell populations.
Therefore, increases in the number of progenitor cells that are
outside the S-phase as a result of rhG-CSF pretreatment before
CPA administration, might lead to an increase in the number of
residual surviving progenitor cells. This, in turn, could reduce the
depression in total progenitorcell counts afterCPA administration,
and prevention ofneutropenia could potentially be achieved.
To examine this possibility, we designed two protocols based
on differences in the timing ofrhG-CSF pretreatment in conjunc-
tion with CPA administration. In group A, in which CPA was
administered when the number of progenitor cells outside the S-
phase was at a minimum as a result ofrhG-CSF pretreatment, the
total number of progenitor cells, S-phase progenitor cells and
neutrophil cells after CPA administration was more depressed
than in the control group and the post-treatment group. This
timing of rhG-CSF pretreatment seemed to render neutropenia
much more serious than neutropenia in the absence of rhG-CSF
treatment. In contrast, in group B, in which CPA was administered
when the number of progenitor cells outside the S-phase had
reached a peak, the nadir of the progenitor cell population was
increased and recovery of the S-phase progenitor cell was
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promoted. In this group, neutrophil recovery was more acceler-
ated than in the other groups and neutrophil recovery seemed to
be supported by the increase in actively proliferating progenitor
cells. These results suggest that the nadirs of neutrophil and pro-
genitor cell counts after CPA administration are closely related to
the number of progenitor cells outside the S-phase when CPA is
administered, and that the effects of pretreatment with rhG-CSF
differ in accordance with the timing of administration relative to
CPA treatment.
Although these data were based on an experimental model,
the possibility of protection against neutropenia by rhG-CSF
pretreatment before CPA administration was observed. However,
this depression did not appear to be due to neutrophil exhaustion
before CPA administration (Morstyn et al, 1989). Rather, it
appeared to be due to the decrease and delayed recovery of
progenitor cell populations after CPA administration, which was
caused by a decrease in the number of progenitor cells outside
the S-phase. In contrast, the severity of neutropenia and the
decrease in progenitor cell populations after CPA administration
could be reduced by increasing the number of progenitor cells
outside the S-phase when CPA was administered. This observa-
tion raises the possibility that more effective timing of rhG-CSF
treatment, other than post-treatment, to reduce the severity of
neutropenia after chemotherapy is possible. These observations
also suggest that the kinetics ofprogenitor cell populations when
chemotherapeutic agents are administered seems to play an
important role in neutropenia after chemotherapy, and that not
only peripheral neutrophil cell and total progenitor cell counts
but also progenitor cell kinetics should be taken into considera-
tion when administering rhG-CSF treatment against the effects
ofchemotherapy.
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